Podcasts about Phase

From Corporate Ladder to Freedom: The Franchise Path to Business OwnershipGuest: Doris Fink, President of Plan B 2000 Inc | Host: Julie RigaOverviewJulie sits down with Doris Fink, who turned an unexpected $300,000 opportunity into two decades of helping professionals create their Plan B. Doris shares her journey from single mom working three jobs to successful business owner, revealing the truth nobody talks about—why the first two years are hardest and how franchise ownership provides the structure that makes all the difference. If you're stuck in corporate America or ready for your Phase 2 career, this conversation will inspire you to leap with clarity and confidence.About This EpisodeDoris and Julie explore Phase 1 versus Phase 2 careers, the power of structure in entrepreneurship, and why passion alone isn't enough. Doris shares authentic insights including sleepless nights, tough decisions, and realizing she'd built someone else's dream—plus practical guidance for professionals ready for business ownership with purpose.Guest BackgroundDoris Fink, President of Plan B 2000 Inc, has over 20 years helping professionals build lives of freedom, fulfillment, and legacy through smart business ownership. Her journey spans healthcare executive to diagnostic business owner to franchise success.Fun Fact: Favorite dessert is sunshine cake with chocolate in the frosting.Key TopicsThe Entrepreneurship Journey:A $300,000 opportunity that changed everythingPhase 1 (career you need) vs. Phase 2 (career you want)Years 1-3 truth: Year 3 is when you turn the cornerThree Ingredients for Success:Interest in business developmentGreat interpersonal skillsBusiness sense or knowing where to get help Bonus: A clear WHYMemorable Quotes"I had just built somebody else's dream.""Year 1 you're covering expenses. Year 2 becomes steady. Year 3 you see earning capability and believe it will work.""Follow your heart and get advice from someone walking the walk, not just talking the talk."Financial RealityYear 1: Investment phase, expenses outweigh incomeYear 2: Steady but supplementalYear 3: The turning pointCapital needs often misunderstoodWho Should Consider ThisProfessionals 45-65 who've climbed the ladder, been passed over or laid off, or asked to compromise values. Anyone with sleepless nights knowing they need change—with family support and right timing.The Passion TrapDon't confuse passion with business sense. Many love pets but a pet business might be wrong. Find the intersection of interest, skill set, and market opportunity.Plan B 2000 ApproachNo-fee, no-pressure consultations assessing family support, timing, capital, and skills. Doris builds friendships, not just client relationships.Questions to AskDo I have the energy?Do I have the personality for uncertainty?Do I have family support?Is timing right?What's my WHY?Connect with Doris FinkLinkedIn: Doris Fink (in Florida, not Germany!)Company: Plan B 2000 IncKey TakeawaysCorporate skills transferStructure accelerates successYear 3 is the turning pointFamily support essentialGet guidance from experienced advisors.Final Wisdom"Try the sunshine cake!" But seriously: "Follow your heart. Just do what you feel is right and get advice from someone who has the experience and not only is talking the talk but is walking the walk."Perfect for anyone in corporate America wondering "is there something more?" and leaders ready to create their Plan B with clarity and confidence.

Most consultants start their business without a clear roadmap. They rely on referrals, hustle and hope. In this episode, I break down Phase 1 of the Scalable Consulting Firm Method: the Foundations Phase, from $0 to $200K in revenue. Whether you're consulting full time or part time, this stage can feel intense. You're learning how to deliver client work and run a business at the same time. I share common mistakes to avoid, what to prioritize and why keeping things simple will serve you best. I also share what kind of coaching support is most helpful at this stage, including how to find the right program or coach to help you build a strong foundation. P.S. I don't typically work with consultants in this phase, but I want you to have the roadmap so you know what to focus on now and when it makes sense to seek deeper support.   Resources Mentioned

If your consulting business is between $200K and $400K, it may look successful from the outside but feel surprisingly unstable on the inside.  In this episode, I break down why Phase 2 is one of the most challenging stages of growth and why so many consultants feel stretched thin, busy, and at the edge of their capacity.  You will also learn what needs your focus in this phase so your business can become more predictable and less dependent on you. This episode will help you understand what is normal, what to expect, and how to move forward with more clarity and confidence. Be sure to follow or subscribe so you do not miss the next episode in the Growing Pains series where scalable operations becomes the focus. Let's Work Together!

Vielleicht feiert ihr eure Freiheit, hängt lieber mit euren Friends ab und habt null Bock auf eine Beziehung. Vielleicht hat sich einfach noch nichts ergeben – und das ist für euch okay. Oder ihr wünscht euch Nähe und merkt, wie der Druck von außen nervt. Und dann gibt's die, die quasi nie Single waren: seit der Schulzeit zusammen, Beziehung on lock. Wie erlebt ihr Single sein – als Freiheit, Frust oder Phase?

1/8. FDR's 1936 Campaign Begins Amid Loss and Opposition from the Right — David Pietrusza — Pietrusza'sbook Roosevelt Sweeps Nation details the opening phase of FDR's 1936 reelection campaign, commencing with the April death of Franklin D. Roosevelt's principal political advisor, Louis Howe, a devastating personal and strategic loss. Roosevelt immediately confronted sharp opposition from the political right, spearheaded by his former mentor Al Smith, who aligned with the wealthy American Liberty League. Roosevelt strategically leveraged Smith's challenge to wage an aggressive class warfare campaign emphasizing wealth redistribution and populist appeals. 1936

Penn State battled back and forth with Rutgers in a game that featured more than 1,000 total yards, ultimately earning a third straight win and bowl eligibility. What stood out during and after the matchup as the Nittany Lions enter an unpredictable timeline? Enjoy complete Penn State coverage anytime at Lions247.com. Follow the team on X: @Lions247 @TDsTake @danieljtgallen @tyler_calvaruso @MarkXBrennan. Follow or subscribe to the Lions247 Podcast on Spotify, Apple Podcasts, Stitcher, or wherever you get your podcasts. And watch every episode on YouTube. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Lamell McMorris talks about his book "The Power to Persist: 8 Simple Habits to Build Lifelong Resilience." Lamell is founder and CEO of Phase 2 Consulting and a nationally recognized entrepreneur and a devoted advocate for equity and community revitalization. Listen for three action items you can use today. Host, Kevin Craine Do you want to be a guest? https://Everyday-MBA.com/guest Do you want to advertise on the show? https://Everyday-MBA.com/advertise

The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬ (COI)Sophia Ambruso @sophia-kidney.bsky.socialSwapnil Hiremath @hswapnil.medsky.social and on LinkedInSpecial Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies)Editing and Show Notes byNayan Arora @captainchloride.bsky.socialThe Kidney Connection written and performed by Tim YauShow NotesProteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed)The number, quality, and coverage of randomized controlled trials in nephrology (PubMed 2004)Updated here (PubMed | NephJC discussion)A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction (PubMed 2017)BLISS Belimumab in lupus nephritis (NephJC | PubMed) The Phase 2 trial of atacicept A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy (PubMed)The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (PubMed | NephJC)Christos' Bluesky post:https://bsky.app/profile/christosargyrop.bsky.social/post/3m5bsujwg3s2q The use of Gd-IgA1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy (PubMed)If you can't get enough Jon Barratt, take a look at his grand rounds at The University of Ottawa. Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt (YouTube)Tubular SecretionSwapnil Hiremath Pluribus on Apple TV (Wikipedia)Jon Barratt Lynyrd Skynyrd (Wikipedia) Slow Horses (Wikipedia) on AppleTVJoel Topf the new ASN

For months, the Trump administration and industry groups have been asserting that EU regulations on methane emissions could result in a sharp decline in — or even an end to — U.S. LNG flows to the EU.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children's Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:05 – Origins of the study, need to pursue more standardized care in IESS 4:40 – Reasons behind treatment variability after first and second-line options 8:00 – What research is needed to guide sequencing and standardize care 12:05 – Neurology News Minute 14:30 – What makes IESS studies difficult and how infrastructure can improve 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

US-Tech-Konzerne erleben meist einen steilen Aufstieg, dann einige Dekaden Höhenflug und schließlich einen langsamen Niedergang. Microsoft stand kurz vor Phase drei – da kam Satya Nadella.

Christian Wolf hat mit More Nutrition ein Multimillionen-Unternehmen aufgebaut – und spricht offen über seinen Weg von Depression zur finanziellen Freiheit. In dieser Episode von selbst&frei teilt Christian seine ungeschönte Wahrheit über den Weg zum Erfolg. Er erklärt, wie er durch Zufall auf Social Media gestoßen ist – ein Video für eine Facebook-Gruppe wurde zu seinem Wendepunkt mit 10.000 Abonnenten über Nacht. Davor war er in einer tiefen depressiven Phase, wusste dass er etwas ändern musste, hatte aber keinen Plan. Christian spricht ehrlich darüber, wie er sich selbst sagte: "Jetzt habe ich schon diese Chance bekommen, wenn ich die nicht nutze, werde ich mich mein Leben lang selbst hassen." Von da an postete er mindestens zwei Videos pro Woche, beantwortete jeden Kommentar und lernte Video-Editing – ohne zu wissen, dass er sich Hilfe hätte holen können. Besonders wertvoll: Seine konkrete Anleitung für den Start. Christian erklärt, warum Erfolg planbar ist und wie du Skill-Ladders ausnutzen kannst. Du erfährst, warum Social Media der offensichtlichste Hebel ist und wie du durch kostenloses Arbeiten für erste Kunden Proof aufbaust. Er teilt seine "First Principles" von Social Media: Mehrwert liefern, Aussagen immer belegen und dabei Quellen nutzen, die gegen deine Interessen sprechen – für maximale Glaubwürdigkeit. Christian spricht offen über seine Mitarbeiter wie Tim, der in zwei Jahren von der Hotelrezeption zum unverzichtbaren Video-Editor wurde – durch Arbeitsmoral und selbstständiges Mitdenken. Besonders eindrucksvoll: Seine Definition von finanzieller Freiheit. Für Christian geht es nicht um Zahlen, sondern um die Freiheit, spontan eine Safari für neun Freunde zu buchen oder beide Familienseiten zu Weihnachten einzuladen. Er erklärt, warum er seine Kinder nicht zur Schule schicken wird und stattdessen mit Privatlehrern und praktischen Erfahrungen arbeitet. Die wichtigste Erkenntnis: Du hast immer das Gefühl, die Hälfte von dem zu brauchen, was du hast, um dich sicher zu fühlen – egal auf welchem Level. Deswegen musst du definieren, was du wirklich willst. Denn wie Christian sagt: "Education ist immer wertvoller als Entertainment – und Proof ist Everything." Mehr zu Christian:Instagram: ⁠https://www.instagram.com/christianwolff/⁠The Quality Group: ⁠https://www.tqgg.de/⁠ Kapitel: (00:00:00) Intro: Von Depression zum Multimillionär (00:01:42) Der Zufallsmoment: Das erste virale Video (00:02:45) Erfolg ist planbar: Die wichtigsten Skill-Ladders (00:03:52) Von 0 auf 1: Der konkrete Weg zum ersten Erfolg (00:05:51) Arbeitsmoral schlägt Talent: Die Pascal-Story (00:06:30) Geduld vs. Amazon Prime Mentalität (00:07:32) Personal Branding: Erst die Credibility, dann Social Media (00:13:38) Instagram vs. YouTube: Die richtige Plattform-Strategie (00:16:25) Der größte Fehler: Auf Zahlen statt auf Zielgruppe optimieren (00:39:03) Content-Ideen: Polarisieren, Educaten, Wiederholen (00:34:31) Der harte Start: Wie es wirklich war (00:47:30) Finanzielle Freiheit: Was braucht man wirklich? (00:52:39) Familie und Exit-Strategie: Die nächsten 10 Jahre (01:00:05) Die harten Wahrheiten: Education, Proof und Durchhaltevermögen  selbst&frei wird im Auftrag von Vivid Money produziert – dem Geschäftskonto für Unternehmer.

The latest annual UN climate conference, COP 30, is coming to a close. Already a failure, the delegates of doom who gathered in Brazil decided that they needed a serious goal to cap off the conference. What did they come up with? Nothing less than the coming up with a concrete roadmap for the complete phase-out of fossil fuels. They might as well have agreed on drawing out a roadmap to Neverland, because that's just as likely to be found as a future with zero use of fossil fuels. The Heartland Institute's Jim Lakely, Sterling Burnett, and Linnea Lueken will be joined by special guests Craig Rucker of CFACT, who just got back from COP 30 in Brazil, and Tony Heller, one of the most-popular and influential climate realism communicators in America. We will also cover also cover some of the Crazy Climate News of the Week, including an exodus from EPA, what climate policy failure looks like in graph form, perhaps the cringiest moment in COP history, and Donald Trump's call to have those who have pushed climate alarmism investigated. Join us LIVE at 1 p.m. ET on YouTube, Rumble, X, and Facebook. Visit our sponsor, Advisor Metals: https://climaterealismshow.com/metals In The Tank broadcasts LIVE every Thursday at 12pm CT on on The Heartland Institute YouTube channel. Tune in to have your comments addressed live by the In The Tank Crew. Be sure to subscribe and never miss an episode. See you there!Climate Change Roundtable is LIVE every Friday at 12pm CT on The Heartland Institute YouTube channel. Have a topic you want addressed? Join the live show and leave a comment for our panelists and we'll cover it during the live show!

In den USA wächst die Kritik an Donald Trump – auch aus den eigenen Reihen. Noch hat der Präsident seine Republikaner im Griff, aber die Risse in seiner Macht sind unübersehbar. Ist er doch ein Politiker wie jeder andere? Vordergründig sieht alles gut aus: Die US-Börse steht trotz Einbußen noch immer gut da. Die Inflation liegt bei rund drei Prozent, weit weg von den Werten seines Vorgängers Joe Biden. Die Bauwirtschaft und der Energiesektor profitieren von einem ungebremsten KI-Boom. Und dennoch ist US-Präsident Trump in der wohl schwierigsten innenpolitischen Krise seiner Karriere. In dieser Ausgabe von »Acht Milliarden« spricht Host Juan Moreno mit dem Leiter des SPIEGEL-Auslandsressorts, Mathieu von Rohr. Die Frage ist, ob Trump den Kipppunkt seiner zweiten Präsidentschaft erreicht hat. Die Kritik kommt von allen Seiten, auch aus den eigenen Reihen: Republikaner im Kongress verlangen die Herausgabe der Epstein-Akten, die Bauern im Mittleren Westen leiden unter den Sojazöllen, überzeugte MAGA-Wähler müssen sich auf höhere Krankenversicherungsbeiträge einstellen. Der US-Präsident wirkt zudem müde und ausgelaugt und nimmt deutlich weniger Termine wahr als in seiner ersten Amtszeit. Man habe den Eindruck, dass Trump langsam in die »Lame duck«-Phase seiner Präsidentschaft hineingleiten könnte, so von Rohr. Mehr zum Thema: (S+) Anschlag in Washington, D.C.: Nahe dem Weißen Haus fallen Schüsse. Und Trump wittert eine Chance – von Julia Amalia Heyer und Frank Hornig: https://www.spiegel.de/ausland/schuesse-auf-nationalgardisten-in-washington-d-c-donald-trump-sieht-sich-bestaetigt-a-b069826e-8516-4643-ad91-bc83df6b7312 (S+) Paramilitärische Truppe ICE: Trumps treue Häscher – von Britta Kollenbroich: https://www.spiegel.de/ausland/usa-so-macht-die-regierung-von-donald-trump-jagd-auf-migranten-a-743ae5d6-8297-4b59-9910-172901cd335e (S+) Hatz auf Einwanderer in den USA: »Sie nehmen schwangere Frauen fest, lauern vor Grundschulen, stürmen Wohnungen« – ein Interview von Jörg Schindler: https://www.spiegel.de/ausland/hatz-auf-einwanderer-in-den-usa-das-ist-beaengstigend-nah-dran-an-einem-konzentrationslager-a-2cc01613-92a2-4990-9b8d-dae6348c431c Abonniert »Acht Milliarden«, um die nächste Folge nicht zu verpassen. Wir freuen uns, wenn ihr den Podcast weiterempfehlt oder uns eine Bewertung hinterlasst. +++ Alle Infos zu unseren Werbepartnern finden Sie hier. Die SPIEGEL-Gruppe ist nicht für den Inhalt dieser Seite verantwortlich. +++ Den SPIEGEL-WhatsApp-Kanal finden Sie hier. Alle SPIEGEL Podcasts finden Sie hier. Mehr Hintergründe zum Thema erhalten Sie mit SPIEGEL+. Entdecken Sie die digitale Welt des SPIEGEL, unter spiegel.de/abonnieren finden Sie das passende Angebot. Informationen zu unserer Datenschutzerklärung.

Middle East correspondent Jacob Brown spoke to Lisa Owen about officials actively working towards the second phase of the Gaza Ceasefire deal, as well as Pope Leo who is due to visit the Middle East on his first trip out of Italy since taking over.

The latest annual UN climate conference, COP 30, is coming to a close. Already a failure, the delegates of doom who gathered in Brazil decided that they needed a serious goal to cap off the conference. What did they come up with? Nothing less than the coming up with a concrete roadmap for the complete phase-out of fossil fuels. They might as well have agreed on drawing out a roadmap to Neverland, because that's just as likely to be found as a future with zero use of fossil fuels.The Heartland Institute's Jim Lakely, Sterling Burnett, and Linnea Lueken will be joined by special guests Craig Rucker of CFACT, who just got back from COP 30 in Brazil, and Tony Heller, one of the most-popular and influential climate realism communicators in America. We will also cover also cover some of the Crazy Climate News of the Week, including an exodus from EPA, what climate policy failure looks like in graph form, perhaps the cringiest moment in COP history, and Donald Trump's call to have those who have pushed climate alarmism investigated.Join us LIVE at 1 p.m. ET on YouTube, Rumble, X, and Facebook.Visit our sponsor, Advisor Metals: https://climaterealismshow.com/metals In The Tank broadcasts LIVE every Thursday at 12pm CT on on The Heartland Institute YouTube channel. Tune in to have your comments addressed live by the In The Tank Crew. Be sure to subscribe and never miss an episode. See you there!Climate Change Roundtable is LIVE every Friday at 12pm CT on The Heartland Institute YouTube channel. Have a topic you want addressed? Join the live show and leave a comment for our panelists and we'll cover it during the live show!

Behind every great community is a mentor who showed someone the way. David Schmit, founder of Schmit & Associates, joins Host Carol Morgan on the Atlanta Real Estate Forum Radio podcast to discuss why thoughtful design and collaboration matter in today's housing market. Designing Walkable Neighborhoods People Love If given the chance to design his dream community anywhere, Schmit says he'd choose “a hillside in Italy.” He values close, human-scaled communities that feel personal to residents. “We used to design everything around the car,” he says. “But magic happens when scale shifts from the car to the person.” Schmit sees density as a tool for creating vibrant communities that connect residents with their environment. Instead of “endless” subdivisions, he favors smaller villages, mixed-use developments and thoughtful, pedestrian-first layouts. Putting Thoughtful Design in Place One of Schmit & Associates' signature projects is Harmony in Auburn, Georgia, a collaboration with Mayor Linda Blechinger that began in 2017. What started as a need to relocate City Hall grew into a broader vision for revitalizing the town center. Working with designer Lew Oliver and landscape expert P. Allen Smith, Schmit helped shape a community of affordable homes, surrounded by lush landscaping and unique details, including pollinator gardens and intimate green spaces. Phase two is underway, and the completed project will include nearly 300 homes priced from the $300,000s to $400,000s. In Acworth, Schmit again partnered with the public sector — this time alongside the JW Collection. On a highly visible, three-acre site in downtown Acworth, the team crafted a walkable mix of residential and commercial space. “The idea was to create this really close-knit space integrated into the downtown area with walkability at its core,” said Schmit. “There are townhomes, mixed-use buildings with commercial spaces, and there’s a restaurant that I’ll be building to put my son into business. That will be a bar with craft cocktails and elevated pub food.” Schmit also teamed with Integral Group to revive Carver Village, a long-dormant Atlanta Housing Authority site along Pryor Road. The first phase includes 227 homes priced from the $300,000s to $500,000s, and future plans include retail and build-to-rent opportunities. What Makes a Schmit & Associates Community? Across every project, Schmit says four guiding principles shape the design: Natural Environment: He wants to understand the land, including its edges, textures and trees, to better determine what opportunities are available. Human Experience: How will residents live, work and gather? Every Schmit & Associates community is developed with a “lead with people” mentality. Built Environment: Schmit emphasizes the importance of designing structures that support resident lifestyles. Whether through walkability or flexible floor plans, he develops communities that allow residents to thrive. Economics of Community: Schmit considers both private returns and public benefits such as growth, community vibrancy and long-term value before beginning a new project. Inside Five Men: A Story of Mentorship and Meaning Schmit's new book, Five Men, explores how mentorship has shaped his personal and professional life. Told in a conversational style, the book weaves Schmit's experiences with five mentors who shaped his life: his father, a high school baseball coach, a priest, the late Dr. Brisbane Brown and two career guides. Schmit said, “The story is about the essence of these relationships and what mentoring can mean in your career path.” Today, Schmit meets regularly with young professionals and encourages them to seek meaningful connections. He challenges them to ask questions while building strong relationships with those around them. Schmit said, “Ask the question, be bold and keep the word ‘relentless' in your vocabulary, which means you just don’t stop.” Tune into the full episode to learn more about upcoming Schmit & Associates' communities and how mentorship drives industry success. To learn more about Schmit & Associates, visit www.SchmitAssociates.com. Schmit's book, Five Men, is available on Amazon. The post Schmit & Associates: How Collaboration Shapes Better Communities appeared first on Atlanta Real Estate Forum.

As the world electrifies—from cars and buses to datacentres and defence—demand for battery materials is exploding. Today, China refines more than 90% of the world's graphite into the material used in virtually all EV battery anodes—that level of concentration is a strategic vulnerability Canada, and its allies, can't ignore.But Canada is starting to respond. The federal Major Projects Office has just referred Nouveau Monde Graphite's Phase-2 Matawinie Mine as a “Major Project of National Interest”—a move aimed at helping Quebec and Canada shift from exporting ore to building a full mine-to-refine graphite value chain at home, and with it, an entirely new strand of economic and industrial capacity.In this episode of Disruptors: The Canada Project, host John Stackhouse takes listeners into that story. With former Quebec premier Jean Charest and Eric Desaulniers, founder & CEO of NMG, he lifts the hood on what it means for a critical-minerals project to be treated as a “major project” in Canada—and what this could mean for Canada's role as a trusted critical-minerals supplier to its G7 allies. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, host Dr. Kristine Smith speaks with Mr. James Bates. They discuss the recently published Original Article: “A Phase 1 Research Trial to Evaluate the Safety and Effectiveness of Intranasal Botulinum Toxin Type A Spray for Patients With Rhinitis.” The full manuscript is available in the International Forum of Allergy and Rhinology. Listen […]

John Cash and Wesley Pipes discuss "The H** Phase" and whether it's essential growth or just cute chaos plus two hilarious stories you have to hear to believe!!   #JohnCashShow #Relationships #Comedy #Laughter #Stories #Tales #Love #Life

Spürst du in dir die steigende Unruhe, den Druck und die Spannung, die gerade in der dunklen Winterzeit besonders spürbar werden?Das ist kein Zufall – genau jetzt ist die beste Zeit zum Loslassen! 

Live Recorded Set from VirtualDJ Radio Hypnotica

Program notes:1:25 mRNA flu vaccine2:25 Phase three trial3:25 Preventing infection with a respiratory virus4:25 Prophylaxis with NSAID?4:45 Umbrella review of acetaminophen in pregnancy, ASD and ADHD5:42 Confidence was low to critically low6:45 Other factors such as environmental exposures7:22 Increasing potassium to prevent heart arrythmias8:33 Increase with supplements or dietary advice9:18 Canceling funding for clinical trials10:18 In the process of receiving interventions11:18 Can't not analyze 12:15 End

Welcome to Phase 4 Podcast. I'm thrilled to introduce today's guest: a man whose journey began with a dream of professional football and then into building a purpose-driven coaching brand that now reaches beyond fitness.Luke Beastall is the founder of MuscleCoach UK, a high-performance coach for entrepreneurs and professionals, and the host of Beyond the Boardroom. With authenticity, grit, passion, and a keen business mind, Luke helps people master their time, elevate their performance and lead with purpose. He's been honoured with a Global Recognition Award for impact in leadership and community development.Tune into a fun and inspiring conversation about dreams, health and wealth!****If you enjoyed this episode, please follow the show, share it with a friend and consider leaving a review on Spotify ⁠https://open.spotify.com/show/4JfM1ZitoXTP6DXXfUbqRm?si=9f68c2de30a5446f⁠  ****www.youtube.com/@Phase4PodcastConnect with Luke https://www.musclecoach.org/ https://www.linkedin.com/in/luke-beastall-720a2591/?originalSubdomain=uk Beyond The Boardroom Podcast https://podcasts.apple.com/be/podcast/beyond-the-boardroom-master-your-life/id1728892626 Connect with Jp ⁠⁠https://linktr.ee/NextStepsAcademy  Are YOU thinking about starting a podcast? Then you need this! ⁠⁠https://www.eventbrite.fr/e/how-to-start-a-podcast-in-2026-with-no-experience-tickets-1707862234919?aff=oddtdtcreator⁠⁠Free Meditation: https://nextstepsacademy.thinkific.com/products/digital_downloads/free Next Steps Academy https://www.thenextstepsacademy.com/ 

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, you'll meet two participants from the TEAMS Study, a research study at the University of Illinois Chicago's UI Health, in conjunction with the University of Alabama Birmingham School of Public Health. TEAAMS is an acronym for Targeted Exercise for African-Americans with Multiple Sclerosis. And the study's research team analyzed the effects of a remotely delivered, racially tailored exercise training program among African Americans with MS living in low-income areas of the Southeastern United States, including Alabama, Georgia, Mississippi, North Carolina, South Carolina, Louisiana, Arkansas, and Tennessee. This is a part of the country that doesn't have many primary care or MS clinics that provide full exercise and rehabilitation services for patients with MS. The TEAMMS study consists of two 16-week exercise programs, completed 3 days per week at home. One exercise program combines aerobic and resistance training, while the other focuses on stretching and flexibility. Study participants were randomly assigned to one of the two programs, and all of the materials to complete each program, like yoga mats, resistance bands, and training manuals, were provided. And every study participant receives a $90 gift card in compensation for completing the program. The study's research team hypothesizes that completing the TEAAMS program would improve walking, reduce symptoms of fatigue, anxiety, depression, and pain, and enhance quality of life. This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct3 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Defense technology has shifted from a social liability in Silicon Valley to commanding 35-40% of venture capital allocation—up from a historical 10%. This isn't just trend-following; it reflects fundamental market dynamics as SaaS becomes hypercompetitive and AI lowers barriers to entry, pushing capital toward deep tech where moats still exist. Blacklake, a defense holdco based in Austin, helps emerging defense companies navigate government procurement and expand into Europe, Asia-Pacific, and allied markets. In this episode, Jeff Crusey, EVP of Technology & Acquisition at Blacklake, reveals the emerging defense tech playbook, explains why lobbying ROI dwarfs traditional GTM spending, and details what actually matters when hardware meets government procurement. Topics Discussed: Why VC capital is rotating from SaaS to deep tech and defense The defense tech go-to-market playbook versus enterprise SaaS mechanics SBIR grant programs as non-dilutive capital for hardware development Lobbying and appropriations as core revenue drivers, not nice-to-haves Field deployment and operator feedback as the only viable iteration strategy Investor evaluation criteria for hardware-intensive defense businesses Emerging threat vectors in Arctic defense and orbital domain awareness GTM Lessons For B2B Founders: Launch lobbying concurrent with SBIR Phase 1 applications: Companies initiating lobbying and appropriations work at the moment they apply for SBIR grants hit revenue milestones materially faster than those treating government affairs as a later-stage function. This means seed-stage companies maintain Capitol Hill presence—a pattern that didn't exist five years ago. The talent profile matters: government affairs hires need proven relationships within specific congressional committees and appropriations staff. Initial engagements typically involve external lobbying advisors with established networks, transitioning in-house at Series A when contract pipeline justifies dedicated headcount. This is consistently the highest-ROI channel in defense GTM. Optimize for deployment speed over system perfection: Modern conflict operates as continuous technological adaptation where capabilities become obsolete within weeks, not years. Companies achieving persistent field presence with operators—not laboratory perfection—win iterative cycles. The tactical approach: deploy minimum viable hardware to operational environments, capture real-world performance data and failure modes, then rapidly incorporate feedback into next iterations. This contradicts traditional defense procurement assumptions about "exquisite systems" and requires founders to resist over-engineering before battlefield validation. Solve the prototype funding problem through non-dilutive capital: Defense investors require working prototypes before capital deployment due to hardware risk profiles—fundamentally different from software's low marginal cost of iteration. This creates a chicken-and-egg problem: prototypes require capital, but capital requires prototypes. The solution path combines bootstrapping to early proof-of-concept, then leveraging SBIR Phase 1 grants (tens of thousands) to reach demonstrable prototype stage. Phase 2 awards (single-digit millions) fund production validation. Strategic founders pursue direct-to-Phase-2 pathways when possible, compressing the timeline from concept to validated demand signal. Strip technical complexity from investor communications: Defense founders with deep domain expertise consistently over-index on technical sophistication during fundraising conversations, losing investor attention before reaching commercial traction narratives. VCs evaluate market timing, defensibility, and path to scale—not engineering elegance. The correction: communicate technology at middle-school comprehension levels. This isn't condescension; it's recognizing that capital allocators optimize for portfolio construction, not technical peer review. Founders often feel they're "dumbing down" their innovations, but clarity on problem-solution fit and market size matters infinitely more than technical specifications during early fundraising stages. Treat SBIR phases as progressive demand validation, not just funding: The phased SBIR structure functions as government-backed demand signaling: Phase 1 validates concept feasibility, Phase 2 confirms development viability, Phase 3 demonstrates production readiness for potential program of record status. Investors decode these phases as risk reduction milestones. Phase 1 awards indicate government interest; Phase 2 awards (especially direct-to-Phase-2 or enhanced Phase 2) signal validated customer pull; Phase 3 contracts position companies for program of record awards worth hundreds of millions annually. Beyond capital, SBIR progression provides founder-market fit evidence and customer commitment that traditional LOIs cannot match in defense contexts. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

What if the very things Satan uses to whisper, “you're too broken, too messy, too late” are the exact things God wants to use to bless His children?In this episode of the Memoirs of an LDS Servant Teacher Podcast, Maurice Harker (founder of Life Changing Services and creator of the Spiritual Psychology Masterclass) dives into the psychology behind fear, perfectionism, and “I'll just mess it up” thinking. From mission stories in Detroit to the story of Martin Harris and the 116 pages, Maurice explains how perfect love casteth out fear and why God invites us into His work knowing full well that we are still in process.You'll hear powerful insights on seeing yourself as one vital chess piece on God's board, learning when to move and when to “hold still,” and why your anger at the pain in the world is actually a form of Christlike love when it drives you to get tools to those who are suffering. Maurice and Markel also share about their new “Phase 3” effort—a project to turn deeply wounded, resilient Latter-day Saint women into an army of healers and creators who bring hope to others.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

Brian, Blake, and Richard are back for Episode 592 of the Chasing Tone Podcast - What's happening to the price of US guitars, the rise of the robots, and Brian's goth phase  Blake has a wallet bursting conundrum as not one but two of his favorite bands are on the same bill and he needs help which Brian and Richard are more than happy to not give. Richard bores Brian to near death with Pink Floyd related updates and then talks about his new old music discoveries. Richard has AI based concerns and he expresses them via the medium of terrible analogies. Brian is not convinced that he is right but there is a business idea and a possible confession. The horrors persist for Richard as he discusses a brand new release from Gibson and Brian taunts him with emojis. There are some language barriers that need to be broken down and there is much confusion. Marshall have released an amp in conjunction with Spinal Tap and Brian ponders the possibilities of an infinitely loud amplifier. Fishing, The Great British Bake off, Ticket Touts, The nuttercut, Lorries...it's all in this week's Chasing Tone!We are on Patreon now too!Support the show (https://www.patreon.com/chasingtonepodcast)Awesome Courses and DIY mods:https://www.guitarpedalcourse.com/https://www.wamplerdiy.com/Youtube:https://www.youtube.com/@chasingtonepodcastFind us at:https://www.wamplerpedals.com/https://www.instagram.com/WamplerPedals/https://www.facebook.com/groups/wamplerfanpage/Contact us at: podcast@wamplerpedals.comSupport the show

This episode kicks off a four-part series exploring each stage of the path to mastery—Startup, Stability, Success, and Mastery. Today, we're diving into how to not just survive the startup phase but step up and own your role as a true business owner.We'll talk about the roadblocks to expect, how to avoid the “shiny object syndrome,” and the value of getting guidance from someone who understands your goals and journey.So listen to real client stories, take in the insights, and let's get you winning through your startup phase!Learn more in The Coaching Equation - Path to Mastery: How to Survive the Startup Phase and Avoid the Fatal Mistakes That Kill 90% of New Coaching BusinessesEnjoy the podcast? Subscribe and leave a 5-star review!Brook Bishop spent over two decades immersed in Personal Development and Business Consulting, driven by a passion for unlocking the potential of coaches and coaching organizations. As the co-founder of EMPIRE Partners, his journey is defined by transformative roles: leading sales at Buffini and Company, the world's largest real estate coaching company, and serving as Tony Robbins' Executive of Business Solutions for 15 impactful years.Connect with Brook Bishop!Website: https://brookbishop.com/ Instagram: https://www.instagram.com/brookthebishop1/ LinkedIn: https://www.linkedin.com/in/brookbishop/ Facebook: https://www.facebook.com/brookthebishop Ryan Lang is the CEO of EMPIRE Partners and a highly sought-after performance coach and consultant. He helps establish business owners, coaches, and thought leaders transform from elite practitioners to transformational leaders by building businesses on five critical pillars instead of one wobbly leg. Over 20 years, he has guided 1000+ professionals to predictable, profitable growth using his Whole Performance Coaching methodology—combining sales mastery, strategic marketing, and human optimization principles that create lasting stability.Connect with Ryan Lang!Website: https://www.ryanrlang.com/ Instagram: https://www.instagram.com/realryanlang/ LinkedIn: https://www.linkedin.com/in/ryan-lang-b46a545b/ Facebook: https://www.facebook.com/ryan.lang.984 Learn more about Empire Partners: Website: https://empirepartners.net/ LinkedIn: https://www.linkedin.com/company/empire-partners/Facebook: https://www.facebook.com/profile.php?id=100093312203714 #PathToMastery #StartupSuccess #BusinessGrowth 

Die deutsche Industrie steckt aktuell in einer schwierigen Phase. Im August gab es den stärksten Produktionseinbruch seit 2022. Was bedeutet das für die Wirtschaft und wie geht es weiter? „Der Monat August ist natürlich prädestiniert für Ferien. Es gab auch einige Werksferien. Die Industrie bewegt sich aber auch seit Jahren seitwärts. Am härtesten betroffen ist die Autobranche. Dort ist die Produktion um fast 19 Prozent gesunken. Das zeigt, wie verwundbar dieser Sektor ist und erklärt, warum die Politik da versucht, sich einzubringen und dieser Branche zu helfen. Die Frage ist aber, inwieweit diese Hilfe zukunftsorientiert ist", sagt Manuel Koch. Der Chefredakteur von Inside Wirtschaft weiter: „Kurzfristig wird keine schnelle Erholung erwartet. Manche Experten rechnen mit einer leichten Stabilisierung. Das wäre ja schon mal was, aber insgesamt bleibt die Konjunktur sowieso schwach. Das dritte Quartal dürfte für die deutsche Wirtschaft auch negativ ausfallen. Der Aufschwung, den wir uns vielleicht auch durch den Politikwechsel erhofft haben, der ist noch nicht angekommen." Alle Details im Interview von Finanzjournalistin Jessica Schwarzer an der Frankfurter Börse und auf https://inside-wirtschaft.de

Most service business owners make the same hiring mistake: they either clone themselves or swing too far in the opposite direction. Dave MacDonald, founder of The MacDonald Group, has cracked the code on bringing in leadership that elevates your business without losing what makes it profitable. In this episode, Dave shares his battle-tested approach to hiring leaders who bring proven systems from larger operations—without the disconnect that kills profitability. If you've ever wondered how to scale past $10M, $20M, or beyond without chaos, this conversation is your roadmap. The "Descending Ladder" Hiring Strategy That Changes Everything Dave's counterintuitive approach: hire leaders from companies roughly double your size. Not too small (they won't bring new systems), not too large (they'll lose touch with the hands-on work that drives profit). The sweet spot: If you're running a $20M service business, target leaders from $40M firms. They've seen the systems that work at scale, but they're still close enough to remember the grind. The danger zone: Hiring someone from a $100M operation for your $20M business. They'll design systems for problems you don't have yet—and profitability vanishes while they build their empire. "Throw Them in the Pool" - The Onboarding System That Reveals Everything Forget the standard two-week onboarding playbook. Dave's approach tests what really matters: can they swim when unexpected challenges hit? Phase 1 - The Pool Phase 2 - The Brick Phase 3 - Juggling The Three I's: Building a Culture That Repels the Wrong People Dave's non-negotiable cultural framework filters out mismatches before they become expensive problems: Integrity - Takes a full year to truly assess. You can't shortcut this one. Intensity - Either they match your pace or they don't. Create an environment where low intensity feels awkward. Intentionality - Can be taught, but natural focus is gold. Look for people who think three steps ahead. Systems That Actually Improve (Instead of Just Existing) The Annual Rewrite: Every Standard Operating Procedure gets completely rewritten yearly. Yes, completely. This forces evolution and prevents "we've always done it this way" from killing your growth. The Weekly Rhythm Feedback loops that matter The People-First AI Strategy for Service Businesses Dave's refreshingly practical take on AI: "Old-world values with today's most robust technology." What they're actually using AI for: Writing and presentation creation Back-office automation (invoicing, payroll) Initial candidate screening What they're NOT doing: Chasing bleeding-edge tools that aren't proven Replacing the human connection in recruiting Top-down AI mandates Why This Matters for Your Service Business If you're stuck between $5M and $20M, you're probably missing one thing: leaders who've already solved the problems you're facing. The systems you need exist—you just need someone who's lived them. Dave's approach removes the guesswork. Hire people who've already built what you're trying to build. Test them hard and fast. Build a culture so strong that mediocrity feels uncomfortable. Most importantly: don't let your systems gather dust. Annual rewrites might sound exhausting, but it's the difference between a business that scales and one that plateaus. Want to transform your hiring and onboarding systems? These aren't just recruitment tactics—they're the foundation for scalable growth. The question isn't whether you can afford to implement these systems. It's whether you can afford not to.

If you've ever wondered what it actually takes to generate consistent, predictable, and sustainable $10K–$50K months as a personal trainer, health coach, nutritionist, or registered dietitian… this episode lays out the entire blueprint step by step.Inside this episode, Beverley pulls back the curtain on the exact systems, structure, and strategy required to build a coaching business that produces dependable revenue month after month — without relying on trends, hacks, freebies, or burnout hustle.Whether you're scaling past your first 10K month or setting your sights on 50K+ months, this is your complete roadmap.⭐ In This Episode, You'll Discover:

In this episode, I talk honestly about the struggles we all face as child-centered play therapists — not as problems to be avoided, but as essential parts of our own therapeutic journey. After two meaningful conversations this week, and in the context of my own recent grief, I've been reflecting on how CCPT doesn't just grow our clients; it grows us. I share how every CCPT clinician eventually hits a wall of resistance, self-doubt, and frustration, and why that moment is actually the turning point toward mastery if we stay the course. I draw parallels between the phases children move through in the playroom and the phases we go through as clinicians — initiation, resistance, work, and ultimately a long, steady season of competence and grounded confidence. This episode is a reminder that resistance is not a sign you're doing something wrong. It's a sign that you're becoming who you're meant to be as a CCPT therapist. When we trust the process for ourselves the same way we trust it for our kids, we emerge stronger, clearer, and more connected to the work than ever. PlayTherapyNow.com is my HUB for everything I do! playtherapynow.com. Sign up for my email newsletter, stay ahead with the latest CCPT CEU courses, personalized coaching opportunities and other opportunities you need to thrive in your CCPT practice. If you click one link in these show notes, this is the one to click! Topical Playlists! All of the podcasts are now grouped into topical playlists on YouTube. Please go to https://www.youtube.com/kidcounselorbrenna/playlists to view them. If you would like to ask me questions directly, check out www.ccptcollective.com, where I host two weekly Zoom calls filled with advanced CCPT case studies and session reviews, as well as member Q&A. You can take advantage of the two-week free trial to see if the CCPT Collective is right for you. Ask Me Questions: Call ‪(813) 812-5525‬, or email: brenna@thekidcounselor.com Brenna's CCPT Hub: https://www.playtherapynow.com CCPT Collective (online community exclusively for CCPTs): https://www.ccptcollective.com Podcast HQ: https://www.playtherapypodcast.com APT Approved Play Therapy CE courses: https://childcenteredtraining.com Facebook: https://facebook.com/playtherapypodcast Common References: Cochran, N., Nordling, W., & Cochran, J. (2010). Child-Centered Play Therapy (1st ed.). Wiley. VanFleet, R., Sywulak, A. E., & Sniscak, C. C. (2010). Child-centered play therapy. Guilford Press. Landreth, G.L. (2023). Play Therapy: The Art of the Relationship (4th ed.). Routledge. Landreth, G.L., & Bratton, S.C. (2019). Child-Parent Relationship Therapy (CPRT): An Evidence-Based 10-Session Filial Therapy Model (2nd ed.). Routledge. https://doi.org/10.4324/9781315537948 Benedict, Helen. Themes in Play Therapy. Used with permission to Heartland Play Therapy Institute.

Brazil's environment minister Marina Silva is calling on nations to commit to a voluntary and "self-determined" fossil-fuel phaseout roadmap at COP30. Debate continues over how aggressive nations should be and how such a roadmap should be enforced. Source: https://www.theguardian.com/environment/2025/nov/16/have-courage-to-create-fossil-fuel-phaseout-roadmap-at-cop30-brazilian-minister-urges Sodium-Ion Batteries That Work at -100°C Researchers at Purdue University have demonstrated a sodium-ion battery capable of operating reliably in extreme cold. The pouch cell was tested with real wind and solar inputs, raising possibilities for remote, polar, and space applications. Lightning Round At COP30 there are 50 fossil-fuel lobbyists for every delegate from the Philippines. The IEA's latest oil-demand forecast assumes no EV growth outside China and Europe—an assumption that defies basic economics and was influenced by Trump-era pressure. Sky debuts a silent, zero-emission hydrogen + sodium battery power system for film and TV sets. Story: https://fcw.sh/RgGKB0 Contact Us cleanenergyshow@gmail.com or leave us an online voicemail: http://speakpipe.com/clean Support The Clean Energy Show Join the Clean Club on our Patreon Page. Our PayPal Donate Page offers one-time or regular donations. Store Visit The Clean Energy Show Store      

Turn online alignment into an offline community — join us at TheWayFwrd.com to connect with like-minded people near you. Have you ever wondered if your phone is quietly rewiring your brain? In this episode, I sit down with Tristan Scott, an electrical engineer turned health researcher who's helping build healthier technology at Daylight Computer. He bridges two worlds that rarely meet: the precision of electrical engineering and the intuition of human biology. And what he's discovered is that our digital tools might be draining more than just our attention. We explore why grounding and sunlight matter more than most people realize, what really happens when EMFs meet the body's own electrical system, and why "energy efficiency" might be costing us our health. Tristan is designing tech that respects human circadian biology instead of hijacking it at Daylight Computer. Because our bodies are already electrical systems, the question is whether we're working with that power or against it. You'll Learn: [00:00] Introduction [00:10:56] The surprising link between Bitcoin, health, and personal sovereignty [00:23:04] Why grounding into your power outlet may be harming you more than helping [00:45:20] The shocking truth about electromagnetic "mind control" experiments [01:03:43] How energy-efficient design quietly removed healing infrared light from our lives [01:09:52] Why working outdoors can literally recharge your biology [01:11:43] The hidden power of cold exposure and mitochondrial uncoupling [01:13:38] Why modern environments are breaking down the body's fourth phase water [01:48:41] When sensitivity returns, your body finally knows what's real [01:55:13] The real reason children lose themselves to screens, and how to fix it Resources Mentioned: Bitcoin and Beef by Tristan Scott | Book or AudiobookThe Way Forward episode on Tuning the Zodiac & Balancing Through Sound featuring Eileen McKusick | Listen NowThe Way Forward episode on The 4th Phase of Water: The Blueprint for Biological Energy with Dr. Gerald Pollack | Listen NowThe Invisible Rainbow by Arthur Firstenberg | Book or AudiobookDanny Hamilton's SunSense | WebsiteCross Currents by Robert Becker | BookThe Body Electric by Robert Becker & Gary Selden | BookThe Anxious Generation by Jonathan Haidt | Book or AudiobookPollock's Paper on Oxygen is an Electron Donor | TelegramThe Brain That Changes Itself by Norman Doidge M.D. | Book or AudiobookJoe Rogan Experience #1235 - Ben Greenfield | Spotify or AppleThe Creature from Jekyll Island by G. Edward Griffin | BookDecentralized Radio Podcast with Tristan Scott and Ryan Brown | Spotify or AppleAires Tech – EMF Protection Devices | WebsiteBio Geometry | Website Visit daylightcomputer.com and use the Code TWF50 for $50 Off. Become a Member of TWF, receive $75 off. Find more from Tristan: Daylight Computer | Website Daylight Computer | InstagramDaylight Computer Kids | WebsiteDaylight Computer Kids | InstagramTristan Scott | XTristan Scott | InstagramTristan Scott | Substack Find more from Alec: Alec Zeck | InstagramAlec Zeck | XThe Way Forward | Instagram   The Way Forward is Sponsored By: RMDY Academy & Collective: Homeopathy Made Accessible High-quality remedies and training to support natural healing.  Enroll here Explore here   New Biology Clinic: Redefine Health from the Ground Up Experience tailored terrain-based health services with consults, livestreams, movement classes, and more. Visit www.NewBiologyClinic.com and use code TheWayForward for $50 off activation. The Way Forward members get the $150 fee waived

This episode includes: #RateMyMeal, teacher makes club gains, oatmeal, nutrition while at theme parks, forearm training and new releases!Join The SwoleFam https://swolenormousx.com/membershipsDownload The Swolenormous App https://swolenormousx.com/swolenormousappMERCH - https://papaswolio.com/Watch the full episodes here: https://rumble.com/thedailyswoleSubmit A Question⁠ For The Show: https://swolenormousx.com/apsGet On Papa Swolio's Email List: https://swolenormousx.com/emailDownload The 7 Pillars Ebook: https://swolenormousx.com/7-Pillars-EbookTry A Swolega Class From Inside Swolenormous X: https://www.swolenormousx.com/swolegaGet Your Free $10 In Bitcoin: https://www.swanbitcoin.com/papaswolio/   Questions? Email Us: Support@Swolenormous.com

Being a caregiver for a loved one with MS isn't an easy job. And, while it may consume hours of your time, often, it's not your only job. Many caregivers are the only family members bringing in an income. So, in addition to their caregiving responsibilities, they may also be facing the responsibilities that go along with holding down a full-time job.  This week, Diana Grazio joins me to discuss how she balances her roles and responsibilities as her partner's caregiver while holding down a full-time job.  You have online opportunities tomorrow! Participate in the National MS Society's Hispanic LatinX MS Experience Summit, or catch the International Progressive MS Alliance's global webcast, How Existing Drugs Could Transform MS Treatment. We have all the info for you to register for either or both!   If you purchase your health insurance through the ACA Healthcare Marketplace, you've probably already been notified that your premiums will skyrocket in 2026. MS Activist, Sarah Quezada, shares how those premium increases will affect her family. Roche has announced the outcomes of Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS. It's positive news, and we have the details! Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  University of Illinois researchers say yes! We're sharing the details. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: It's National Family Caregiver Month  :22 The MS Care Partner Connection  :34 The National MS Society is hosting the Hispanic LatinX MS Experience Summit TOMORROW!  2:20 The International Progressive MS Alliance Global Webcast is TOMORROW!  2:51 Sarah Quezada shares how astronomical increases in ACA health insurance premiums will affect her family  3:46 Roche announces outcomes for Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS  11:59 Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  13:43 Diana Grazio discusses how she manages her role as a caregiver while holding down a full-time job  16:07 Share this episode  29:10 Next week's episode  29:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/429 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Online Survey https://s.alchemer.com/s3/Perspectives-on-MS SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy REGISTER: The Hispanic LatinX MS Experience Summit https://nationalmssociety.org/resources/get-support/education-programs-and-library/hispanic-latinx-ms-experience REGISTER: International Progressive MS Alliance Global Webcast https://msif.org/news/2025/11/03/alliance-webcast VISIT: The MS Care Partner Connection https://mscarepartnerconnection.com STUDY: Nanoparticle-Boosted Myeloid-Derived Suppressor Cell Therapy for Immune Reprogramming in Multiple Sclerosis https://www.science.org/doi/10.1126/sciadv.ady4135 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 429 Guests: Sarah Quezada, Diana Grazio Privacy Policy

In this conversation, we discuss the challenges and strategies involved in navigating the first building phase of muscle growth. We explore the psychological side of body image, the importance of mindset, and how nutrition supports long-term progress. We highlight the need for self-acceptance, the importance of managing expectations during physical changes, and the value of community support throughout the journey of personal growth and strength training. Find us on Instagram here: Level Up: https://www.instagram.com/levelup_podcast_/ Sharelle: https://www.instagram.com/sharellegrant/ Dani: https://www.instagram.com/daniantonellos/

The orexin receptor agonists are coming. After years of managing narcolepsy with stimulants, sodium oxybate, and wake-promoting agents, we soon will have medications that target the root cause of the disorder: the loss of orexin signaling. These new drugs—developed by Takeda, Alkermes, and Centessa—aren't just incremental improvements. They represent a genuine shift in how we understand and treat hypersomnolence disorders. In this episode, we will:Define what orexin is and why losing it destabilizes wakefulness, REM boundaries, muscle tone, and cognitionLearn how orexin agonists work—not as stimulants, but as replacement therapy for a missing neurotransmitterFind out why OX2R is the key receptor, and how selective agonists restore stable wakefulness, reduce cataplexy, and normalize attentionReview the available clinical data from the new wave of programs: oveporexton (Takeda), alixorexton (Alkermes), and ORX750 (Centessa)See what makes these drugs different from modafinil, amphetamines, solriamfetol, and oxybate therapiesLearn why Phase 1, Phase 2, and Phase 3 trials matter—with quick insights on how these drugs reached such strong resultsConsider safety and side effects, including what Hy's Law means and why regulators watch liver signals so closelyLook ahead to what these medications may mean for NT1, NT2, IH, and other hypersomnolence disorders in the coming yearsSpeculate why this class represents one of the most exciting moments in modern sleep medicineProduced by: Maeve WinterMore Twitter: @drchriswinter IG: @drchriwinter Threads: @drchriswinter Bluesky: @drchriswinter The Sleep Solution and The Rested Child Thanks for listening and sleep well!

This is the morning All Local update for November 17, 2025.

Recording date: 14th November 2025The precious metals sector is experiencing a convergence of favorable conditions that veteran investors describe as one of the best commodity setups in decades. At the recent Precious Metals Summit in Zurich, industry leaders including Pierre Lassonde, Frank Giustra, and Marc Faber highlighted observable market fundamentals supporting this outlook: global liquidity at record highs, structural demand emerging from technological infrastructure, and mining companies generating unprecedented cash flows while trading at reasonable valuations.Global liquidity continues expanding despite recent volatility. The People's Bank of China maintains liquidity injections, while the New York Fed has announced plans for substantial liquidity injection into US markets during Q1 2026. The recent government shutdown ending will release capital trapped in the treasury system for over a month. This liquidity expansion creates sustained support for precious metals as fiat currency purchasing power deteriorates.A less obvious but transformative demand driver emerges from artificial intelligence infrastructure development. The US needs to build at least 350 gigawatts of power dedicated to AI infrastructure—equivalent to 50 nuclear power plants—representing a trillion-dollar investment cycle for power generation alone. This excludes electrical grids, transmission infrastructure, and computing hardware. Recent government partnerships with Brookfield, Cameco, and Westinghouse for nuclear facility development signal the beginning of infrastructure spending requiring massive copper, steel, and concrete quantities while necessitating continued government liquidity injection supportive of gold prices.Third quarter 2025 results demonstrated the financial leverage inherent in gold mining operations. AngloGold Ashanti increased quarterly operating cash flow from $300 million to $1.4 billion—more than quadrupling while gold prices doubled. Even accounting for the Centamin acquisition contributing 20% of production, cash flow expansion significantly exceeds gold price appreciation. The company now operates with zero net debt, increased dividends, and strategic flexibility for acquisitions or capital returns while trading at roughly half the valuation of Agnico Eagle Mines despite comparable cash generation.K92 Mining offers equally compelling value, posting six consecutive quarters of free cash flow while organically funding construction of a complete new mill, twin declines, and associated infrastructure. The Phase 3 expansion completing commissioning in Q4 2025 will drive significant cash flow growth as throughput increases with minimal incremental operating costs. Operating costs scale favorably—an 800 tonne per day mill requires similar oversight as a 3,000 tonne per day mill. Market valuations have not yet reflected this coming cash flow expansion, creating opportunity for investors who understand the timeline and trust management execution.The M&A cycle is accelerating as producers with pristine balance sheets deploy capital. Recent examples include B2 Gold taking a 19.9% stake in Prospector Generator (now funded with $40 million for 2026 exploration), Probe Gold's acquisition, New Gold's pending takeover, and Gold Fields committing $50 million to junior investments. The competition for quality assets remains in early stages despite this activity.Investment opportunities span the market capitalization spectrum: established producers generating record profits at reasonable valuations, funded developers approaching major cash flow inflections, and well-backed exploration companies positioned for discoveries. Current Q4 volatility represents tactical entry opportunities before typical Q1 seasonal strength, with multiple fundamental drivers supporting sustained outperformance of real assets over the coming decade.Learn more: https://cruxinvestor.comSign up for Crux Investor: https://cruxinvestor.com

Matt is joined by Bloomberg's Lucas Shaw to investigate a historically bad fall season at the box office by highlighting which issues are actually real and which are insignificant. They look at larger industry-wide trends, like the shortening of theatrical windows and the rise of streaming, as well as smaller, more recent developments like releasing independent movies wide rather than platforming them. They discuss whether the "movie-star problem" excuse is overblown or legitimate, as well as if this could simply be explained by judging the actual quality of the films themselves (02:33). Matt finishes the show with an Academy Awards prediction after attending the premiere of Netflix's ‘Jay Kelly' (25:54). For a 20 percent discount on Matt's Hollywood insider newsletter, ‘What I'm Hearing ...,' ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Email us your thoughts! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠thetown@spotify.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Host: Matt Belloni Guest: Lucas Shaw Producers: Craig Horlbeck and Jessie Lopez Theme Song: Devon Renaldo Learn more about your ad choices. Visit podcastchoices.com/adchoices

LSD shows promise for anxiety treatment. A Phase 2b clinical trial found that 100 micrograms of MM120 (pharmaceutical LSD) reduced anxiety significantly with lasting effects Study results were encouraging. Researchers noted that 65% of participants experienced clinical response at optimal dosing, with 47.5% achieving remission that sustained through 12 weeks of follow-up Safety profile was manageable. Most side effects occurred during dosing sessions and resolved quickly, with visual changes and nausea being most common under medical supervision Note that LSD remains illegal. It is currently classified as Schedule I controlled substance, accessible only through approved clinical trials, with results of Phase 3 trials expected by 2026 In the meantime, natural anxiety alternatives exist. Breathing techniques like nasal breathing, horizontal breathing patterns, and controlled breathing practices can help manage anxiety symptoms without medication

For the second time in 4 weeks, Jim "Smitty" Smith joins Joe for an "off the cuff" podcast conversation! Specific topics discussed include: Behind-the-scenes insight into Phase 2 of Built Different; A nuanced approach to training variability (and programming in 4-week blocks); 3 things that the "happiest people in the world" always have; Valuable gym lessons from high achievers; How to get your weaker limb stronger in record time; Remembering Mike Mentzer; The difference between "science-based coaches" & "science-based KIDS"; How to blow up your biceps in ONE iNsAnE set...And so much more! *For a full list of Show Notes + Timestamps visit www.IndustrialStrengthShow.com. IMPORTANT LINKS Team Forever Strong [FREE Trial] Iron Business Blueprint [Apply Now] Smitty's Instagram Joe D's Instagram Manukora Honey

Carl Rivera is the Chief Design Officer at Shopify, where he previously led both Merchant Services and the Shop App as VP of Product. Before joining Shopify through its acquisition of Tictail, Carl was the co-founder and CEO of Tictail, the "Tumblr for e-commerce," where he built one of the most beloved design-forward commerce platforms of its era. AGENDA: 05:05 Biggest Lessons from Selling My Company to Shopify 09:55 Where Does Shopify Suck at Product: Lessons from that? 17:37 What makes Truly Great product Design: The Five Pillars 31:02 The Future of Design in an AI-Driven World 36:00 Do We Skip the Design Phase in AI: Figma's Evolving Role in Design 40:09 Remote Work vs. In-Person Collaboration: Where Remote Loses? 42:43 What Happens to the Vibe Coding Market 47:06 Product Management and Team Dynamics 59:48 Does AI Favour Incumbents or Startups  

Send us a text if you want to be on the Podcast & explain why!Most new trainers don't fail because they're lazy—they fail because they were set up to memorize, not to coach. We sit down with Cori, a dedicated runner navigating NASM overwhelm, and turn tangled chapters into clear, usable coaching. You'll hear how to translate planes of motion into exercises you can demo immediately, how to spot agonists and antagonists without guessing, and how to use synergists and stabilizers to make your cues land.We walk through the OPT model the way hiring managers want to hear it: Phase 1 builds control and competency, Phase 2 pairs stable with less stable for smarter supersets, Phase 3 drives muscle, Phase 4 loads heavy for strength, and Phase 5 blends power and strength with purpose. You'll get a no-fluff take on energy systems and fiber types—anchored to duration and intensity—so exam questions become quick wins. Then we make assessments useful: identify what “arms fall” and “knees cave” really mean, apply the red-versus-green muscle lists, and choose fixes that actually change movement. Foam roll and stretch what's tight, strengthen what's sleepy, and cue breathing and bracing so reps look and feel better.Safety and screening matter, so we hit the essentials: PAR-Q, hypertension basics, the SA node, and knowing when to refer out. More importantly, we show how hands-on learning, live feedback, and mentorship build confidence faster than any textbook—because clients won't ask about amortization, they'll ask for results. If you've been grinding through chapters and still feel stuck, this conversation gives you a study map, coaching language, and a training method you can use tomorrow.If this helped you see the path more clearly, follow the show, share it with a trainer friend, and leave a quick review—it helps more future coaches find their footing.Want to ask us a question? Email email info@showupfitness.com with the subject line PODCAST QUESTION to get your question answered live on the show! Our Instagram: Show Up Fitness CPT TikTok: Show Up Fitness CPT Website: https://www.showupfitness.com/Become a Personal Trainer Book (Amazon): https://www.amazon.com/How-Become-Personal-Trainer-Successful/dp/B08WS992F8NASM / ACE / ISSA study guide: https://www.showupfitness.com/collections/nasm

Mike Maloney: Gold, Silver Bull Run in Final Phase, I Expect "Spectacular" Prices Mike Maloney of ‪@Goldsilver explains why this time really is different for gold and silver, pointing to factors including growing mainstream adoption, and noting that much more of the world's population is able to buy precious metals than in previous cycles. "This is just like a whole new world — this to me signals the beginning of the third and final phase of the bull market — and that is where you have the greatest amount of gains in the shortest period of time. So we should be seeing some fireworks coming," he said.   Watch this video at- https://youtu.be/Yl7B9tFCicY?si=JktrazBIo4z-WbCT Investing News 59.9K subscribers 14,720 views Nov 11, 2025 #Investing #Gold #Silver ❓ Is the gold-silver ratio part of your buying strategy? Tell us in the comments! Read free chapters of Mike's book: https://ggsr21.com/ This interview was filmed on November 3, 2025. #Investing #Gold #Silver 0:00 - Intro 1:20 - This time is really different 4:47 - Final phase of bull market 7:49 - "Giant crisis" in the works 11:21 - Trigger for market crash 13:15 - Farmland offers protection 15:25 - Gold-silver ratio strategy 19:47 - Gold, silver price potential 23:11 - Outro ________________________________________________________________ Investing News Network (INN) Find out more about investing by INN @ https://investingnews.com/ Browse our 2025 outlook reports: http://bit.ly/3JHyR1M Follow us on Facebook:   / investing.news.your.trusted.source   Follow us on Twitter: https://x.com/inn_resource

In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants